Company performance
Add to research
Current Price
as of Apr 17, 2025$1.25
P/E Ratio
N/A
Market Cap
$99.39M
Description
Add to research
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.
Metrics
Add to research
Overview
- HQWatertown, MA
- SectorHealth Technology
- IndustryBiotechnology
- TickerCCCC
- Price$1.25+13.64%
Trading Information
- Market cap$99.39M
- Float79.89%
- Average Daily Volume (1m)1,105,370
- Average Daily Volume (3m)1,338,058
- EPS-$1.52
Company
- Revenue$35.58M
- Rev growth (1yr)71.44%
- Net income-$105.32M
- Gross margin77.82%
- EBITDA margin-307.11%
- EBITDA-$109.28M
- EV$70.59M
- EV/Revenue1.98
- P/EN/A
- P/S2.73
- P/B0.46
- Debt/Equity30.44
Documents
Add to research
SEC Filings
Factset Street Account